Table 3.
Results of generalized estimating equation (GEE) models of sCD14 levels as a function of past 30-day alcohol use (Model Set 1) and alcohol use plus clinical and demographic control variables (Model Set 2).
Model Set 1: Alcohol use only |
Alcohol use B (SE) |
p- value |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Average drinks per week |
32.56 (9.50) |
.001 | ||||||||||
Drinking days |
79.98 (23.01) |
.001 | ||||||||||
Heavy drinking days |
111.64 (21.83) |
< .001 | ||||||||||
Drinks per drinking day |
83.41 (116.87) |
.475 | ||||||||||
Days since last drink |
−118.03 (24.73) |
< .001 | ||||||||||
Model Set 2: Alcohol use and control variables |
Alcohol use B (SE) |
p- value |
Age B (SE) |
p- value |
HIV duration B (SE) |
p- value |
Smoking B (SE) |
p- value |
CD4 nadir B (SE) |
p- value |
ART type B (SE) |
p- value |
Average drinks per week |
30.10 (10.65) |
.005 | 67.86 (74.60) |
.363 | −26.51 (75.09) |
.724 | 241.68 (504.75) |
.632 | −1.08 (2.85) |
.704 | −141.06 (1035.72) |
.892 |
Drinking days |
68.08 (24.93) |
.006 | 72.41 (68.32) |
.289 | −41.30 (65.84) |
.531 | 223.47 (483.00) |
.644 | −1.15 (2.85) |
.688 | 1.78 (916.71) |
.998 |
Heavy drinking days |
106.25 (24.82) |
< .001 | 56.89 (75.51) |
.451 | −9.78 (76.14) |
.898 | 62.10 (486.41) |
.898 | −.832 (2.86) |
.771 | −412.16 (993.04) |
.678 |
Drinks per drinking day |
153.43 (102.20) |
.133 | 52.96 (83.21) |
.525 | −8.70 (83.61) |
.917 | 203.89 (534.99) |
.703 | −0.96 (3.00) |
.747 | −430.00 (1194.33) |
.719 |
Days since last drink |
-126.01 (24.15) |
< .001 | 78.53 (70.97) |
.269 | −17.82 (71.07) |
.802 | 788.06 (607.89) |
.195 | −1.64 (3.09) |
.596 | −322.89 (918.66) |
.725 |
Abbreviations: ART = antiretroviral therapy; PI = protease inhibitor.
Notes: Beta coefficients represent change in sCD14 (ng/ml) for a 1-unit change in the predictor. Categorical variables were coded as follows: smoking status, non-smoker = 0 and smoker =1; ART type, protease inhibitor-sparing ART = 0, protease inhibitor-containing ART = 1. Repeating Model Set 2 analyses with current CD4 count instead of CD4 nadir produced comparable results.